43 results
8-K
EX-99.1
NMTRQ
9 Meters Biopharma, Inc.
8 Nov 22
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
8:05am
the Phase 3 protocol during the fourth quarter of 2022.
Clinical plans and activities are underway with our engagement of a global clinical research
424B3
NMTRQ
9 Meters Biopharma, Inc.
4 Aug 22
Prospectus supplement
4:17pm
benefit from treatment with larazotide. Completion of the analyses and engagement with the FDA will determine further plans for larazotide
8-K
EX-99.1
q6hp3iebue
21 Jun 22
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
8:02am
8-K
EX-10.2
nz1ws8qyxyzs 6s
18 Jan 22
9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer
8:05am
8-K
EX-1.1
qo7v9
5 Apr 21
9 Meters Biopharma Announces Proposed Public Offering of Common Stock
4:26pm
8-K
EX-1.1
onl0b8g df
15 Dec 20
9 Meters Biopharma, Inc. Announces Proposed Public Offering of Common Stock
4:25pm
8-K
EX-2.1
sj1n30 vk
4 May 20
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC
5:24pm